Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

By A. Kakkar, M. Levine, Z. Kadziola, N. Lemoine, V. Low, H. Patel, G. Rustin, Michael Thomas, M. Quigley, R. Williamson. Journal of Clinical Oncology, 2004

697 citations recorded by the source corpus.

Subfields: Hepatology, Internal Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/1dcc58ac9d52a8fb11efb2f9ee4ff978c6313f60

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Internal Medicine

1. G. Agnelli
2. S. Konstantinides
3. H. Büller

Citations in the corpus

• Incidence of venous thromboembolism and its effect on survival among patients with common cancers. (2006, neutral): “Prostate 50 926 0 70 33 383 (66) 7041 (14) 3515 (7) 6987 (14) Breast 44 744 99 62 27 014 (60) 13 629 (30) 2029 (5) 2072 (5) Lung 45 215 45 69 6558 (15) 8775 (19) 22 486 (50) 7396 (16) Colon/rectum 32 157 50 71 10 623 (33) 12 766 (40) 6409 (20) 2359 (7) Melanoma 9930 44 55 8065 (81) 431 (4) 466 (5) 9”
• American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. (2021, methodology): “From these reviews, we identified 17 eligible RCTs that fulfilled our inclusion criteria and measured outcomes relevant to this clinical setting.(223-238) One systematic review evaluated the efficacy and safety of LMWH prophylaxis for patients receiving chemotherapy for lung cancer.”
• [2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. (2014, positive): “VKAsareused inmostcases,whileLMWHispreferred in patients with VTE and cancer.(356,357) Three new oral anticoagulant agents have been evaluated in the extended treatment of VTE.”
• ESC Guidelines on the diagnosis and management of acute pulmonary embolism (2014, background): “VKAsareused inmostcases,whileLMWHispreferred in patients with VTE and cancer.(356,357) Three new oral anticoagulant agents have been evaluated in the extended treatment of VTE.”
• Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism (2008, background): “VKAs are used in the vast majority of patients, while LMWH may be an effective and safe alternative to VKAs in cancer patients.(306,307) VKAs should be given at doses adjusted to maintain a target INR of 2.”